Sofinnova Investments, Inc.
Sofinnova Investments, Inc. reported 67 holdings worth US$2.3B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Sofinnova Investments, Inc. reported 67 holdings worth US$2.3B as of Sep 30, 2026. Largest: Natera, Inc., Genmab A/S and Vera Therapeutics, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 67
- Value as reported
- US$2.3B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Natera, Inc. | 1.55M | US$641M | 27.8% |
| Genmab A/S | 4.35M | US$155M | 6.7% |
| Vera Therapeutics, Inc. | 2.79M | US$90.2M | 3.9% |
| Axsome Therapeutics, Inc. | 446K | US$82.2M | 3.6% |
| Seaport Therapeutics, Inc. | 3.56M | US$71.9M | 3.1% |
| Rapport Therapeutics, Inc. | 1.9M | US$64M | 2.8% |
| ArriVent BioPharma, Inc. | 1.7M | US$51.4M | 2.2% |
| Rhythm Pharmaceuticals, Inc. | 535K | US$50.9M | 2.2% |
| Eli Lilly and Company | 43,777 | US$50.7M | 2.2% |
| Dyne Therapeutics, Inc. | 2.51M | US$40.5M | 1.8% |
| Inhibrx Biosciences, Inc. | 392K | US$39.2M | 1.7% |
| IDEAYA Biosciences, Inc. | 946K | US$36.4M | 1.6% |
| Immunome, Inc. | 1.63M | US$35M | 1.5% |
| Novartis AG | 197K | US$28M | 1.2% |
| Alnylam Pharmaceuticals, Inc. | 113K | US$27.9M | 1.2% |
| Ultragenyx Pharmaceutical Inc. | 1.75M | US$26.4M | 1.1% |
| BioMarin Pharmaceutical Inc. | 433K | US$26M | 1.1% |
| Bristol-Myers Squibb Company | 330K | US$20.6M | 0.89% |
| Abbott Laboratories | 207K | US$20.5M | 0.89% |
| United Therapeutics Corporation | 36,491 | US$19.8M | 0.86% |
| Veradermics, Incorporated | 144K | US$17.5M | 0.76% |
| AnaptysBio, Inc. | 330K | US$16.6M | 0.72% |
| BioAge Labs, Inc. | 2.29M | US$16.3M | 0.71% |
| Arcus Biosciences, Inc. | 626K | US$16.2M | 0.70% |
| Edgewise Therapeutics, Inc. | 397K | US$16.1M | 0.70% |
| IDEXX Laboratories, Inc. | 29,145 | US$15.2M | 0.66% |
| Disc Medicine, Inc. | 232K | US$15.2M | 0.66% |
| Design Therapeutics, Inc. | 1.14M | US$14.4M | 0.63% |
| Biogen Inc. | 63,002 | US$14.2M | 0.62% |
| First Tracks Biotherapeutics, Inc. | 384K | US$13.6M | 0.59% |
| Nektar Therapeutics | 218K | US$13.2M | 0.57% |
| Definium Therapeutics, Inc. | 339K | US$12.9M | 0.56% |
| Nurix Therapeutics, Inc. | 524K | US$12.4M | 0.54% |
| Erasca, Inc. | 677K | US$9.93M | 0.43% |
| Tarsus Pharmaceuticals, Inc. | 110K | US$8.66M | 0.38% |
| Silence Therapeutics PLC | 212K | US$2.31M | 0.10% |
| Savara, Inc. | 356K | US$1.84M | 0.08% |
| Septerna, Inc. | 46,217 | US$1.81M | 0.08% |
| Mirum Pharmaceuticals, Inc. | 19,450 | US$1.66M | 0.07% |
| Sagimet Biosciences Inc. - Series A | 162K | US$1.6M | 0.07% |
| Phibro Animal Health Corporation | 43,216 | US$1.54M | 0.07% |
| Jade Biosciences, Inc. | 107K | US$1.51M | 0.07% |
| NextCure, Inc. | 223K | US$1.12M | 0.05% |
| Praxis Precision Medicines, Inc. | 3,703 | US$1.08M | 0.05% |
| Absci Corporation | 80,817 | US$870K | 0.04% |
| OnKure Therapeutics, Inc. | 313K | US$852K | 0.04% |
| Inventiva SA | 210K | US$773K | 0.03% |
| Tyra Biosciences, Inc. | 31,407 | US$687K | 0.03% |
| Aktis Oncology, Inc. | 31,605 | US$615K | 0.03% |
| Bolt Biotherapeutics, Inc. | 138K | US$507K | 0.02% |
| iBio, Inc. | 372K | US$439K | 0.02% |
| Lisata Therapeutics, Inc. | 156K | US$225K | <0.01% |
| ImageneBio, Inc. | 31,884 | US$146K | <0.01% |
| Cogent Biosciences, Inc. | 0 | US$0 | 0.00% |
| Gilead Sciences, Inc. | 0 | US$0 | 0.00% |
| Heartflow, Inc. | 0 | US$0 | 0.00% |
| Insmed Incorporated | 0 | US$0 | 0.00% |
| Sionna Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Supernus Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Tenax Therapeutics, Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related